Search Results - "ROUTLEDGE, Carol"

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial by James, Ellen, Erritzoe, David, Benway, Tiffanie, Joel, Zelah, Timmermann, Christopher, Good, Meghan, Agnorelli, Claudio, Weiss, Brandon M, Barba, Tommaso, Campbell, Graham, Baker Jones, Michelle, Hughes, Charlotte, Topping, Helen, Boyce, Malcolm, Routledge, Carol

“…Due to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as…”
Get full text

Inhibition of IL-34 Unveils Tissue-Selectivity and Is Sufficient to Reduce Microglial Proliferation in a Model of Chronic Neurodegeneration by Obst, Juliane, Simon, Emilie, Martin-Estebane, Maria, Pipi, Elena, Barkwill, Liana M, Gonzalez-Rivera, Ivette, Buchanan, Fergus, Prescott, Alan R, Faust, Dorte, Fox, Simon, Brownlees, Janet, Taylor, Debra, Perry, V Hugh, Nuthall, Hugh, Atkinson, Peter J, Karran, Eric, Routledge, Carol, Gomez-Nicola, Diego

“…The proliferation and activation of microglia, the resident macrophages in the brain, is a hallmark of many neurodegenerative diseases such as Alzheimer's…”
Get full text

Orexin A Activates Locus Coeruleus Cell Firing and Increases Arousal in the Rat by Hagan, Jim J., Leslie, Ron A., Patel, Sara, Evans, Martyn L., Wattam, Trevor A., Holmes, Steve, Benham, Christopher D., Taylor, Stephen G., Routledge, Carol, Hemmati, Panida, Munton, Richard P., Ashmeade, Tracey E., Shah, Ajit S., Hatcher, Jonathan P., Hatcher, Paula D., Declan N. C. Jones, Smith, Martin I., Piper, David C., Hunter, A. Jackie, Porter, Rod A., Upton, Neil

“…The localization of orexin neuropeptides in the lateral hypothalamus has focused interest on their role in ingestion. The orexigenic neurones in the lateral…”
Get full text

Functional MRI Detection of Pharmacologically Induced Memory Impairment by Sperling, Reisa, Greve, Douglas, Dale, Anders, Killiany, Ronald, Holmes, Jennifer, Rosas, H. Diana, Cocchiarella, Andrew, Firth, Paul, Rosen, Bruce, Lake, Stephen, Lange, Nicholas, Routledge, Carol, Albert, Marilyn

“…To examine alterations in brain activation associated with pharmacologically induced memory impairment, we used functional MRI (fMRI) to study the effects of…”
Get full text

The distribution of 5-HT6 receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT6 receptor antagonist [125I]SB-258585 by ROBERTS, Jennifer C, REAVILL, Charlie, EAST, Simon Z, HARRISON, Paul J, PATEL, Sara, ROUTLEDGE, Carol, LESLIE, Ronald A

Get full text

Discovery and In Vitro Characterization of SPL028: Deuterated N,N‑Dimethyltryptamine by Layzell, Marie, Rands, Peter, Good, Meghan, Joel, Zelah, Cousins, Rick, Benway, Tiffanie, James, Ellen, Routledge, Carol

“…The psychedelic N,N- dimethyltryptamine (DMT) is in clinical development for the treatment of major depressive disorder. However, when administered via…”
Get full text

Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials by Langbaum, Jessica B., Zissimopoulos, Julie, Au, Rhoda, Bose, Niranjan, Edgar, Chris J., Ehrenberg, Evan, Fillit, Howard, Hill, Carl V., Hughes, Lynne, Irizarry, Michael, Kremen, Sarah, Lakdawalla, Darius, Lynn, Nancy, Malzbender, Kristina, Maruyama, Tetsuyuki, Massett, Holly A., Patel, Deep, Peneva, Desi, Reiman, Eric M., Romero, Klaus, Routledge, Carol, Weiner, Michael W., Weninger, Stacie, Aisen, Paul S.

“…Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other…”
Get full text

Pharmacokinetics of N,N-dimethyltryptamine in Humans by Good, Meghan, Joel, Zelah, Benway, Tiffanie, Routledge, Carol, Timmermann, Chris, Erritzoe, David, Weaver, Richard, Allen, Graham, Hughes, Charlotte, Topping, Helen, Bowman, Amy, James, Ellen

“…Background and Objective N , N -dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This…”
Get full text

Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study by Routledge, C, Gurling, J, Wright, I K, Dourish, C T

“…The neurochemical profile of the selective 5-HT1A receptor antagonist WAY100135 [N-tert-butyl 3-4-(2-methoxyphenyl) piperazin-1-yl-2-phenylpropanamide…”
Get more information

The DEMON Network: The first UK network for deep dementia phenotyping: Epidemiology / Innovative methods in epidemiology (i.e., assessment methods, design, recruitment strategies, statistical methods, etc.) by Ranson, Janice M, James, Charlotte, Routledge, Carol, Everson, Richard, Bauermeister, Sarah D, Llewellyn, David J

“…Abstract Background Collaborative interdisciplinary research will be key to advances in dementia prevention, identification and treatment. We established the…”
Get full text

The DEMON Network: The first UK network for deep dementia phenotyping by Ranson, Janice M, James, Charlotte, Routledge, Carol, Everson, Richard, Bauermeister, Sarah D, Llewellyn, David J

“…Background Collaborative interdisciplinary research will be key to advances in dementia prevention, identification and treatment. We established the DEMON…”
Get full text

Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses by Redondo-Castro, Elena, Faust, Dorte, Fox, Simon, Baldwin, Alex G., Osborne, Simon, Haley, Michael J., Karran, Eric, Nuthall, Hugh, Atkinson, Peter J., Dawson, Lee A., Routledge, Carol, Allan, Stuart M., Freeman, Sally, Brownlees, Janet, Brough, David

“…Inflammation is an established contributor to disease and the NLRP3 inflammasome is emerging as a potential therapeutic target. A number of small molecule…”
Get full text

The Early Detection of Neurodegenerative diseases initiative: an international and multidisciplinary effort for transforming the early detection of dementia‐causing diseases by Marinaro, Federica, Morvan, Claire, Au, Rhoda, Bond, Simon, Burkhart, Michael C., Carlebach, Nomi, Chan, Dennis, Delbarre, Daniel, Farier, Lisa, Lacey, Aaron, LaMonica, Haley, Lancaster, Claire L, Lee, Liz Yuanxi, Llewellyn, David J, Mallon, Ann‐Marie, Martins, Ralph N, Ardle, Ríona Mc, Mummery, Catherine J., Naismith, Sharon L, Oldham, Mike, Rainey‐Smith, Stephanie, Santos, Luis, Slight, Sarah, Smith, Nadia, Thomas, Spencer, Venton, Jenny, Tolley, Clare, Whitaker, Kirstie, Wright, Joshua, Wilson, Sarah, Wing, Kieran, Crawford, John, Dagum, Paul, Routledge, Carol, Walker, Zuzana, Everson, Richard, Hinds, Chris, Kourtzi, Zoe

“…Background Around 50 million people have dementia worldwide, with nearly 10 million new cases every year. Diagnosis is complex and often relies on expensive…”
Get full text

Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190 by Routledge, Carol, Gurling, Jane, Ashworth-Preece, Mark A., Dourish, Colin T.

“…1-(2-Methoxyphenyl)-4-[(phthalimido)butyl] piperazine (NAN-190) and 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione (buspirone)…”
Get full text

Tackling gaps in developing life-changing treatments for dementia by Mauricio, Rui, Benn, Caroline, Davis, John, Dawson, Gerry, Dawson, Lee A., Evans, Alison, Fox, Nick, Gallacher, John, Hutton, Mike, Isaac, John, Jones, Declan N.C., Jones, Lesley, Lalli, Giovanna, Libri, Vincenzo, Lovestone, Simon, Moody, Catherine, Noble, Wendy, Perry, Hugh, Pickett, James, Reynolds, David, Ritchie, Craig, Rohrer, Jonathan D., Routledge, Carol, Rowe, James, Snyder, Heather, Spires-Jones, Tara, Swartz, Jina, Truyen, Luc, Whiting, Paul

“…Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment…”
Get full text

Kinetic studies on the thiocyanate substitution of water on two incomplete cuboidal tritungsten(IV) oxo sulfido aqua complexes: [W3O2S2(H2O)9]4+ and [W3OS3(H2O)9]4 by Li, Yue Jin, Routledge, Carol A, Sykes, A. Geoffrey

Get full text

Effect of the acute and chronic administration of the selective 5‐HT 6 receptor antagonist SB‐271046 on the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study by Minabe, Yoshio, Shirayama, Yukihiko, Hashimoto, Kenji, Routledge, Carol, Hagan, Jim J., Ashby, Charles R.

“…Abstract This study examined the effect of the acute and repeated per os (p.o.) administration of the selective 5‐HT 6 receptor antagonist SB‐271046, on the…”
Get full text

Development of 5-HT1A receptor antagonists by ROUTLEDGE, C

Get full text

5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046) : A potent, selective, and orally bioavailable 5-HT6 receptor antagonist by BROMIDGE, S. M, BROWN, A. M, MOSS, S. F, NEWMAN, H, RILEY, G, ROUTLEDGE, C, WYMAN, P, CLARKE, S. E, DODGSON, K, GAGER, T, GRASSAM, H. L, JEFFREY, P. M, JOINER, G. F, KING, F. D, MIDDLEMISS, D. N

Get full text

Characterization of SB‐271046: A potent, selective and orally active 5‐HT6 receptor antagonist by Routledge, Carol, Bromidge, Steven M, Moss, Stephen F, Price, Gary W, Hirst, Warren, Newman, Helen, Riley, Graham, Gager, Tracey, Stean, Tania, Upton, Neil, Clarke, Stephen E, Brown, Anthony M, Middlemiss, Derek N

“…SB‐271046, potently displaced [3H]‐LSD and [125I]‐SB‐258585 from human 5‐HT6 receptors recombinantly expressed in HeLa cells in vitro (pKi 8.92 and 9.09…”
Get full text